Emergency reversal of novel oral anticoagulants help is on the way

JAMA Neurology

Volumn 73, Issue 2, 2016, Pages 155-156

  Mayer, Stephan A ^a  

^a MOUNT SINAI HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; CIRAPARANTAG; DABIGATRAN; FRESH FROZEN PLASMA; IDARUCIZUMAB; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; BLOOD CLOTTING FACTOR;

ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CLINICAL PROTOCOL; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; EMERGENCY CARE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEMOSTASIS; HUMAN; MEDICAL DECISION MAKING; MEDICAL EXPERT; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUBDURAL HEMATOMA; TREATMENT OUTCOME; UNITED STATES; CEREBRAL HEMORRHAGE; FEMALE; HEMATOMA; MALE;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CEREBRAL HEMORRHAGE; FEMALE; HEMATOMA; HUMANS; MALE;

EID: 84964713778     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.3884     Document Type: Editorial

References (13)

1. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-1243.
2. Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015;36(20):1264-1272.
3. Hankey GJ, Stevens SR, Piccini JP, et al; ROCKET AF Steering Committee and Investigators. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation. Stroke. 2014;45 (5):1304-1312.
4. Hart RG, Diener H-C, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511-1517.
5. Purrucker JC, Haas K, Rizos T, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants [published online December 14, 2015]. JAMA Neurol. doi:10.1001/jamaneurol.2015.3682.
6. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-520.
7. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446-451.
8. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141-2142.
9. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059-1064.
10. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1):1-5.
11. Frontera JA, Lewin JJ, Rabinstein AA, et al. Reversal of antithrombotics in intracranial hemorrhage: an evidence-based guideline. Neurocrit Care. In press.
12. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573-1579.
13. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217-224.